<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074204</url>
  </required_header>
  <id_info>
    <org_study_id>LILY1503</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CWRU-LILY-1503</secondary_id>
    <secondary_id>LILLY-B9E-US-S245</secondary_id>
    <nct_id>NCT00074204</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase III Study of Delayed vs. Immediate Second-Line Therapy With Docetaxel After Gemcitabine + Carboplatin in Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine, carboplatin, and docetaxel, use&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die. Combining more&#xD;
      than one drug may kill more tumor cells. It is not yet known which treatment regimen is more&#xD;
      effective for stage IIIB or stage IV non-small cell lung cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine and&#xD;
      carboplatin followed immediately by docetaxel with that of giving delayed docetaxel in&#xD;
      treating patients who have stage IIIB or stage IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the overall survival of patients with stage IIIB or IV non-small cell lung&#xD;
           cancer treated with gemcitabine and carboplatin followed by immediate vs delayed&#xD;
           docetaxel.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the response rate and time to progression in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to ECOG performance&#xD;
      status (0 or 1 vs 2).&#xD;
&#xD;
      All patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and carboplatin IV&#xD;
      over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients with stable or responding disease proceed to docetaxel therapy. Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day&#xD;
           1.&#xD;
&#xD;
        -  Arm II (delayed docetaxel): Patients are observed until first evidence of disease&#xD;
           progression and then receive docetaxel IV over 1 hour on day 1.&#xD;
&#xD;
      In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life (QOL) is assessed at baseline, at restaging (after completion of gemcitabine&#xD;
      and carboplatin), before courses 2-6 of docetaxel*, and then at 1 and 3 months after study&#xD;
      treatment.&#xD;
&#xD;
      NOTE: *For patients randomized to delayed docetaxel, QOL is assessed every 3 weeks until&#xD;
      first disease progression and then before courses 2-6 of docetaxel&#xD;
&#xD;
      Patients are followed monthly for 3 months, every 2 months for 6 months, and then every 3&#xD;
      months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 550 patients (275 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Patients are followed monthly for 3 months, every 2 months for 6 months, and then every 3 months thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (partial and complete response)</measure>
    <time_frame>Patients are followed monthly for 3 months, every 2 months for 6 months, and then every 3 months thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by NCI CTC</measure>
    <time_frame>at baseline and at the end of each course not at day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the lung cancer symptom scale</measure>
    <time_frame>At baseline, at restaging, before courses 2-6 of docetaxel*, and then at 1 and 3 months after study treatment. Arm II, QOL is assessed every 3 weeks until first disease progression and then before courses 2-6 of docetaxel.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Immediate Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.</description>
    <arm_group_label>Delayed Docetaxel</arm_group_label>
    <arm_group_label>Immediate Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.&#xD;
Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.&#xD;
In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
    <arm_group_label>Delayed Docetaxel</arm_group_label>
    <arm_group_label>Immediate Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Gemcitabine IV over 30-60 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.</description>
    <arm_group_label>Delayed Docetaxel</arm_group_label>
    <arm_group_label>Immediate Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  Stage IIIB with pleural effusion OR stage IV disease&#xD;
&#xD;
               -  Recurrent disease after primary treatment with radiotherapy or surgery allowed&#xD;
&#xD;
          -  Measurable disease or nonmeasurable disease&#xD;
&#xD;
               -  Measurable disease, defined as at least 1 unidimensionally measurable lesion at&#xD;
                  least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Nonmeasurable disease, defined as all other lesions, including small lesions&#xD;
                  (longest diameter less than 20 mm by conventional techniques OR less than 10 mm&#xD;
                  by spiral CT scan) or any of the following:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusion&#xD;
&#xD;
                    -  Inflammatory breast disease&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
                    -  Abdominal masses not confirmed and followed by imaging techniques&#xD;
&#xD;
          -  No symptomatic CNS metastases&#xD;
&#xD;
               -  Treated, stable CNS metastases allowed provided patient is not receiving&#xD;
                  radiotherapy or corticosteroids&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT no greater than 3.0 times upper limit of normal (ULN) (less than 5.0 times ULN&#xD;
             for patients with documented benign disease)&#xD;
&#xD;
          -  Alkaline phosphatase less than 3.0 times ULN (for patients with documented benign&#xD;
             disease)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No active and ongoing infection&#xD;
&#xD;
          -  No concurrent serious systemic disorder that would preclude study participation&#xD;
&#xD;
          -  No other primary malignancy within the past 5 years except carcinoma in situ of the&#xD;
             cervix, adequately treated basal cell skin cancer, or T1 vocal cord cancer in&#xD;
             remission&#xD;
&#xD;
               -  Other prior cancers unlikely to affect survival for the next 3 years (e.g.,&#xD;
                  low-grade early stage prostate cancer) are allowed&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for NSCLC, including neoadjuvant and adjuvant therapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent antitumor hormonal therapy (excluding contraceptives and replacement&#xD;
             steroids)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  Prior radiotherapy to less than 25% of bone marrow allowed provided the irradiated&#xD;
             area is not the only site of measurable disease&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 3 weeks since prior therapy for cancer&#xD;
&#xD;
          -  More than 4 weeks since prior investigational agents&#xD;
&#xD;
          -  No other concurrent experimental medications&#xD;
&#xD;
          -  No other concurrent therapy for cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan Levitan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Nathan Levitan, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

